<div class="flex max-w-full flex-col gap-4 grow">
<div class="min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+&amp;]:mt-1" dir="auto" tabindex="0" data-message-author-role="assistant" data-message-id="adb75060-c004-46c4-b638-caa2d6cc963b" data-message-model-slug="gpt-5-5" data-turn-start-message="true">
<div class="flex w-full flex-col gap-1 empty:hidden">
<div class="markdown prose dark:prose-invert wrap-break-word w-full light markdown-new-styling">
<h2 data-section-id="xohtcw" data-start="0" data-end="27"><strong>Myasthenia Gravis Market</strong></h2>
<p data-start="29" data-end="726">The <a href="https://www.delveinsight.com/report-store/myasthenia-gravis-market"><strong>Myasthenia Gravis market</strong></a> across the 7MM reached nearly USD 6 billion in 2025 and is projected to grow at a CAGR of 9.1% during 2026&ndash;2036. The rising burden of autoimmune disorders, increasing awareness, and improved diagnostic capabilities are accelerating market expansion. The US accounted for nearly 78% of the total market share in 2025, driven by higher biologic adoption and strong reimbursement support. Emerging FcRn inhibitors and targeted biologics are transforming the treatment landscape and improving long-term disease control. By 2036, efgartigimod alfa and hyaluronidase-qvfc (VYVGART HYTRULO/VYVDURA) are expected to generate the highest revenue among all therapies in the 7MM.</p>
<h3 data-start="728" data-end="750"><strong data-start="728" data-end="750">Key Market Drivers</strong></h3>
<ul data-start="751" data-end="908">
<li data-section-id="3yxc4j" data-start="751" data-end="796">Rising prevalence of autoimmune disorders</li>
<li data-section-id="on607l" data-start="797" data-end="833">Improved diagnostic technologies</li>
<li data-section-id="bo1511" data-start="834" data-end="866">Launch of targeted biologics</li>
<li data-section-id="1ertecw" data-start="867" data-end="908">Expanding innovative therapy pipeline</li>
</ul>
<h2 data-section-id="1olundb" data-start="915" data-end="948"><strong>Myasthenia Gravis Epidemiology</strong></h2>
<p data-start="950" data-end="1634">In 2025, the total diagnosed prevalent cases of <a href="https://www.delveinsight.com/report-store/myasthenia-gravis-epidemiology-forecast"><strong>Myasthenia Gravis</strong></a> across the 7MM were estimated at nearly 300,000 cases. The United States represented the largest share with approximately 46% of total diagnosed prevalent cases, followed by the EU4 and the UK with 43%, while Japan contributed 11%. Epidemiology segmentation includes gender-specific, age-specific, severity-specific, and antibody serology-based diagnosed prevalent cases. The highest disease burden in the US was observed in patients aged 65 years and above, followed by the 50&ndash;64 years age group. Increasing longevity and better recognition of symptoms are contributing to rising prevalence across all age categories.</p>
<h3 data-start="1636" data-end="1665"><strong data-start="1636" data-end="1665">Epidemiology Segmentation</strong></h3>
<ul data-start="1666" data-end="1816">
<li data-section-id="nzhbzq" data-start="1666" data-end="1701">Total diagnosed prevalent cases</li>
<li data-section-id="mve9ul" data-start="1702" data-end="1727">Gender-specific cases</li>
<li data-section-id="f3vupt" data-start="1728" data-end="1750">Age-specific cases</li>
<li data-section-id="ccwf01" data-start="1751" data-end="1778">Severity-specific cases</li>
<li data-section-id="xdn91m" data-start="1779" data-end="1816">Antibody serology-based gMG cases</li>
</ul>
<h3 data-start="1818" data-end="1841"><strong data-start="1818" data-end="1841">MGFA Classification</strong></h3>
<ul data-start="1842" data-end="1958">
<li data-section-id="1dvxeh7" data-start="1842" data-end="1869">Class I: Pure ocular MG</li>
<li data-section-id="1xj10hn" data-start="1870" data-end="1916">Class II&ndash;IV: Mild to severe generalized MG</li>
<li data-section-id="prpms6" data-start="1917" data-end="1958">Class V: Myasthenic crisis/intubation</li>
</ul>
<h2 data-section-id="jpwkbq" data-start="1965" data-end="1994"><strong>Myasthenia Gravis Pipeline</strong></h2>
<p data-start="1996" data-end="2778">The <a href="https://www.delveinsight.com/report-store/myasthenia-gravis-pipeline-insight"><strong>Myasthenia Gravis pipeline</strong></a> is rapidly evolving with several targeted biologics and FcRn inhibitors being developed by leading pharmaceutical companies. Recent approvals, including IMAAVY, have strengthened treatment options for both AChR-positive and MuSK-positive generalized MG patients. Pipeline development is focused on achieving sustained remission, reducing exacerbations, and improving tolerability in refractory disease. Companies such as Argenx, Alexion, AstraZeneca Rare Disease, Johnson &amp; Johnson, UCB, Immunovant, Roivant Sciences, Cartesian Therapeutics, Novartis, and Merck KGaA are actively advancing novel therapies. The growing emphasis on disease-modifying approaches and precision medicine is expected to significantly reshape the future treatment landscape.</p>
<h3 data-start="2780" data-end="2798"><strong data-start="2780" data-end="2798">Approved Drugs</strong></h3>
<ul data-start="2799" data-end="2974">
<li data-section-id="hgn15a" data-start="2799" data-end="2847"><a href="https://www.delveinsight.com/report-store/ultomiris-emerging-drug-insight-and-market-forecast"><strong>ULTOMIRIS</strong></a> - Alexion/AstraZeneca Rare Disease</li>
<li data-section-id="1p24xwi" data-start="2848" data-end="2868">VYVGART - Argenx</li>
<li data-section-id="eh6k53" data-start="2869" data-end="2905">VYVGART HYTRULO/VYVDURA - Argenx</li>
<li data-section-id="2e6pw1" data-start="2906" data-end="2936">IMAAVY - Johnson &amp; Johnson</li>
<li data-section-id="mzycl8" data-start="2937" data-end="2955">ZILBRYSQ - UCB</li>
<li data-section-id="5nvmci" data-start="2956" data-end="2974">RYSTIGGO - UCB</li>
</ul>
<h3 data-start="2976" data-end="2995"><strong data-start="2976" data-end="2995">Key Unmet Needs</strong></h3>
<ul data-start="2996" data-end="3236" data-is-last-node="" data-is-only-node="">
<li data-section-id="abnhxv" data-start="2996" data-end="3050">Poor diagnostic accuracy in seronegative ocular MG</li>
<li data-section-id="fko6t0" data-start="3051" data-end="3097">Lack of early exacerbation detection tools</li>
<li data-section-id="1a0otdt" data-start="3098" data-end="3140">Need for sustained remission therapies</li>
<li data-section-id="1njqtdy" data-start="3141" data-end="3188">Limited tolerable options for refractory MG</li>
<li data-section-id="1q5mwsn" data-start="3189" data-end="3236" data-is-last-node="">Absence of disease-modifying therapies (DMTs)</li>
</ul>
</div>
</div>
</div>
</div>
<div class="mt-3 w-full empty:hidden">
<div class="text-center">
<div class="mx-auto">
<div>
<div class="inline-flex rounded-xl border border-gray-100 dark:border-gray-700">
<div class="me-12 flex items-center px-4 py-3 text-start">&nbsp;</div>
</div>
</div>
</div>
</div>
</div>

Myasthenia Gravis Market Infographic

Myasthenia Gravis Market Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.